Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation THT 2025

Win Ratio Analysis of Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: REBALANCE-HF Randomized Trial

Presenter: Marat Fudim

February 12, 2025

Presentation THT 2025

Left Atrial to Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 2-Year Results

Presenter: Javed Butler

February 11, 2025

Presentation THT 2025

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Presenter: Sanjiv Shah

February 11, 2025

Presentation AHA 2024

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Presenter: Milton Packer

November 16, 2024

Presentation THT 2024

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results

Presenter: Sanjiv J. Shah

March 05, 2024

Presentation THT 2023

Obesity in Heart Failure with Preserved Ejection Fraction: Insights from the REDUCE LAP-HF II Trial

Presenter: Sheldon Litwin

March 21, 2023

Presentation THT 2023

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: Updated Results of the REBALANCE-HF Trial Roll-in Cohort

Presenter: Marat Fudim

March 21, 2023

Presentation ACC 2023

Rate-Adaptive Atrial Pacing for Heart Failure with preserved Ejection Fraction: The RAPID-HF trial

Presenter: Barry A. Borlaug

March 06, 2023

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

Presentation AHA 2016

Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial

Presenter: David M Kaye

November 15, 2016

Advertisement

Win Ratio Analysis of Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: REBALANCE-HF Randomized Trial

Left Atrial to Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 2-Year Results

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results

Obesity in Heart Failure with Preserved Ejection Fraction: Insights from the REDUCE LAP-HF II Trial

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: Updated Results of the REBALANCE-HF Trial Roll-in Cohort

Rate-Adaptive Atrial Pacing for Heart Failure with preserved Ejection Fraction: The RAPID-HF trial

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content